Stockreport

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? [Yahoo! Finance]

MoonLake Immunotherapeutics - Class A Ordinary Shares  (MLTX) 
PDF Cormorant Asset Management disclosed a buy of 2,361,260 shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) in its February 17, 2026 SEC filing, an estimated $27.86 mil [Read more]